Sarepta Therapeutics
SRPT
123 hedge funds and large institutions have $548M invested in Sarepta Therapeutics in 2014 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 41 increasing their positions, 39 reducing their positions, and 24 closing their positions.
190% more call options, than puts
Call options by funds: $110M | Put options by funds: $37.9M
5% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 39
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less funds holding
Funds holding: 128 → 123 (-5)
17% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 24
31% less capital invested
Capital invested by funds: $794M → $548M (-$246M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$23.1M |
| 2 |
CWAM
Columbia Wanger Asset Management
Chicago,
Illinois
|
+$13.6M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$8.28M |
| 4 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$7.8M |
| 5 |
CA
Commerzbank Aktiengesellschaft
Frankfurt,
Germany
|
+$5.74M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$53.7M |
| 2 |
D.E. Shaw & Co
New York
|
-$12.6M |
| 3 |
SFM
Soros Fund Management
New York
|
-$8.01M |
| 4 |
JG
Jefferies Group
New York
|
-$3.92M |
| 5 |
Millennium Management
New York
|
-$2.92M |
SRPT Hedge Fund Activity: Q3 2014 in Review
123 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q3 2014, worth a combined $548M — down 31% from $794M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of SRPT and 20 opened new positions — a net loss of 4 holders — while 39 trimmed existing stakes and 41 added.
The largest buyer was Jennison Associates, opening a new position worth an estimated $23.1M. The largest seller was Lord, Abbett & Co, cutting an estimated $53.7M.
- 123 institutional investors held Sarepta Therapeutics (SRPT) as of Q3 2014, down from 128 in Q2 2014.
- Funds reported $548M of Sarepta Therapeutics stock for Q3 2014, down 31% quarter-over-quarter.
- 20 funds opened new Sarepta Therapeutics positions in Q3 2014 and 24 closed out, a net change of -4 holders.
- The largest Sarepta Therapeutics buyer in Q3 2014 was Jennison Associates, an estimated $23.1M added.
- The largest Sarepta Therapeutics seller in Q3 2014 was Lord, Abbett & Co, an estimated $53.7M sold.
Based on aggregated 13F filings for Q3 2014.